Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a21e9b5438faf814

Jump to content

Lenvervimab

Edit links
From Wikipedia, the free encyclopedia
Lenvervimab
Monoclonal antibody
Type?
SourceHumanized
Targethepatitis B virus surface antigen
Clinical data
Other namesGC1102
ATC code
  • none
Identifiers
CAS Number
DrugBank
UNII

Lenvervimab (INN;[1] development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.[2]

This drug is being developed by GC Pharma. As of 2018, lenvervimab is undergoing Phase II/III trials.

References

[edit]
  1. ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).
  2. ↑ Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH (2020). "A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants". PLOS ONE. 15 (8) e0236704. Bibcode:2020PLoSO..1536704J. doi:10.1371/journal.pone.0236704. PMC 7425877. PMID 32790777.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Lenvervimab&oldid=1330056264"